LGD-4033 vs Masteron
Moderate Research vs Moderate Research
synergistic Mechanism-based · 60% Masteron helps manage estrogen conversion from LGD-4033. This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen.
Molecular Data
LGD-4033 Masteron
Weight 338.25 Da 304.47 Da (base)
Half-life ~24-36 hours ~2 days (propionate), ~10 days (enanthate)
Type Nonsteroidal selective androgen receptor modulator (C14H12F6N2O) DHT-derived anabolic steroid (C20H32O2)
Key Benefits
LGD-4033
01 Strongest SARM for lean muscle mass accrual, with clinical trial data supporting dose-dependent increases in lean body mass
02 Tissue-selective action with minimal stimulation of the prostate and other androgen-sensitive tissues
03 Clinical evidence of improved physical function (leg press strength, stair-climbing speed) in hip fracture patients
04 No aromatization to estrogen (no estrogen-related water retention or gynecomastia at the receptor level)
05 No conversion to DHT (reduced risk of androgenic hair loss and prostate stimulation compared to testosterone)
06 Convenient once-daily oral dosing due to 24-36 hour half-life
07 Phase 2 clinical data available, providing a stronger evidence base than most other SARMs
Masteron
01 Produces a hard, dry, and grainy appearance by eliminating subcutaneous water retention
02 Mild anti-estrogenic properties that can reduce or replace the need for aromatase inhibitors on cycle
03 Does not aromatize, eliminating estrogen-mediated side effects from the compound itself
04 Enhances the visual effects of other steroids in a stack by reducing water retention and bloat
05 Modest increases in strength without significant weight gain, useful for weight-class athletes
06 Improves muscle density and vascularity at low body fat percentages
07 Well-tolerated with a relatively mild side effect profile compared to other anabolic steroids
08 Short detection window with propionate ester compared to many other injectable steroids
Dosing Protocols
LGD-4033
5-10 mg/day / Once daily (oral)
Masteron
300-500 mg/week / Every other day (propionate) or 2x per week (enanthate)
Cutting / Aesthetic Enhancement 300-400 mg/week Every other day (propionate) or 2x per week (enanthate)
Contest Preparation 400-500 mg/week Every other day or daily (propionate)
AI Replacement / Estrogen Management 200-300 mg/week Every other day (propionate) or 2x per week (enanthate)
Side Effects
LGD-4033
Testosterone suppression (dose-dependent; more suppressive than Ostarine at equivalent doses, occurs in most users by week 4-6)
Water retention (non-estrogenic mechanism, typically mild to moderate, contributes to scale weight increase)
HDL cholesterol reduction (dose-dependent lipid impact observed in clinical trials)
Headaches (most common in the first 1-2 weeks, usually transient)
Fatigue or lethargy (related to testosterone suppression, typically becomes noticeable mid-cycle)
Reduced libido (related to HPG axis suppression, severity varies by dose and individual)
Masteron
Hair loss and accelerated male pattern baldness (significant risk as a DHT derivative - the most commonly reported side effect)
Acne and increased skin oiliness, particularly on the back and shoulders
Suppression of natural testosterone production (requires PCT or ongoing TRT)
Injection site pain or discomfort (more common with propionate ester)
Mild aggression or irritability from elevated androgenic activity
HDL cholesterol suppression and adverse lipid profile changes
Contraindications
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer or other androgen-driven malignancies)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient long-term safety data for this population)
History of significant lipid abnormalities (LGD-4033 suppresses HDL)
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males
Pregnancy or potential for pregnancy (causes virilization of female fetus)
Known hypersensitivity to drostanolone or any formulation components
Severe hepatic impairment
Pre-existing significant hair loss where further androgenic exposure is unacceptable
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled cardiovascular disease or severe dyslipidemia
Research Evidence
LGD-4033 Masteron
Status Moderate Research Moderate Research
References 5 studies 5 studies
Latest 2018 March 2020
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.